PMID- 26169666
OWN - NLM
STAT- MEDLINE
DCOM- 20160816
LR  - 20181113
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Print)
IS  - 1053-2498 (Linking)
VI  - 34
IP  - 11
DP  - 2015 Nov
TI  - The impact of pre-transplant allosensitization on outcomes after lung 
      transplantation.
PG  - 1415-22
LID - S1053-2498(15)01290-5 [pii]
LID - 10.1016/j.healun.2015.06.003 [doi]
AB  - BACKGROUND: Allosensitization can be a significant barrier to transplantation for 
      some patients, and previous studies suggested that pre-transplant 
      allosensitization was associated with worse outcomes after lung transplantation. 
      However, human leukocyte antigen (HLA) antibody testing has evolved significantly 
      over the past 10 years, and current assays are highly sensitive and specific. 
      METHODS: We examined the impact of pre-transplant allosensitization on 
      post-transplant outcomes in the era of solid-phase multiplex HLA antibody 
      detection assays in this retrospective, single-center study of 304 adult 
      transplant recipients between January 1, 2006, and December 31, 2012. We accepted 
      donor organs for allosensitized patients if a virtual crossmatch was compatible 
      with all previously identified antibodies. RESULTS: In univariate and 
      multivariate Cox proportional hazards models, pre-transplant allosensitization, 
      the calculated panel reactive antibody, and the number of pre-transplant HLA 
      antibodies were not associated with the development of acute cellular rejection, 
      lymphocytic bronchiolitis, donor-specific HLA antibodies, chronic lung allograft 
      dysfunction, or graft failure. CONCLUSIONS: Pre-transplant allosensitization does 
      not adversely affect outcomes after lung transplantation when the potentially 
      reactive HLAs are avoided in the donor by a virtual crossmatch with the 
      recipient.
CI  - Copyright (c) 2015 International Society for Heart and Lung Transplantation. 
      Published by Elsevier Inc. All rights reserved.
FAU - Bosanquet, James P
AU  - Bosanquet JP
AD  - Division of Pulmonary and Critical Care Medicine.
FAU - Witt, Chad A
AU  - Witt CA
AD  - Division of Pulmonary and Critical Care Medicine.
FAU - Bemiss, Bradford C
AU  - Bemiss BC
AD  - Division of Pulmonary and Critical Care Medicine.
FAU - Byers, Derek E
AU  - Byers DE
AD  - Division of Pulmonary and Critical Care Medicine.
FAU - Yusen, Roger D
AU  - Yusen RD
AD  - Division of Pulmonary and Critical Care Medicine.
FAU - Patterson, Alexander G
AU  - Patterson AG
AD  - Division of Cardiothoracic Surgery.
FAU - Kreisel, Daniel
AU  - Kreisel D
AD  - Division of Cardiothoracic Surgery.
FAU - Mohanakumar, Thalachallour
AU  - Mohanakumar T
AD  - Department of Surgery, Washington University School of Medicine, St. Louis, 
      Missouri.
FAU - Trulock, Elbert P
AU  - Trulock EP
AD  - Division of Pulmonary and Critical Care Medicine.
FAU - Hachem, Ramsey R
AU  - Hachem RR
AD  - Division of Pulmonary and Critical Care Medicine. Electronic address: 
      Rhachem@dom.wustl.edu.
LA  - eng
GR  - R01 HL056643/HL/NHLBI NIH HHS/United States
GR  - HL105412/HL/NHLBI NIH HHS/United States
GR  - R34 HL105412/HL/NHLBI NIH HHS/United States
GR  - T32 HL007317/HL/NHLBI NIH HHS/United States
GR  - HL056643/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150610
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the 
      International Society for Heart Transplantation
JID - 9102703
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Rejection/epidemiology/immunology/*prevention & control
MH  - HLA Antigens/*immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunization/*methods
MH  - Incidence
MH  - Isoantibodies/*immunology
MH  - *Lung Transplantation
MH  - Male
MH  - Middle Aged
MH  - Missouri/epidemiology
MH  - Preoperative Care/*methods
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Time Factors
MH  - Tissue Donors
MH  - *Transplant Recipients
PMC - PMC4619119
MID - NIHMS699421
OTO - NOTNLM
OT  - allosensitization
OT  - lung transplantation
OT  - panel reactive antibody
COIS- DISCLOSURE STATEMENT None of the authors has a financial relationship with a 
      commercial entity that has an interest in the subject of the presented manuscript 
      or other conflicts of interest to disclose.
EDAT- 2015/07/15 06:00
MHDA- 2016/08/17 06:00
PMCR- 2016/11/01
CRDT- 2015/07/15 06:00
PHST- 2015/02/23 00:00 [received]
PHST- 2015/05/01 00:00 [revised]
PHST- 2015/06/02 00:00 [accepted]
PHST- 2015/07/15 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2016/08/17 06:00 [medline]
PHST- 2016/11/01 00:00 [pmc-release]
AID - S1053-2498(15)01290-5 [pii]
AID - 10.1016/j.healun.2015.06.003 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2015 Nov;34(11):1415-22. doi: 
      10.1016/j.healun.2015.06.003. Epub 2015 Jun 10.